OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
796359

Koken Ltd

Medical Equipment, Supplies & DistributionVerified

KOKEN LTD. maintains a conservative capital structure with a debt-to-equity ratio of 0.42, below the industry median of 0.65, indicating a lower reliance on debt financing. The company's liquidity position is characterized by a current ratio of 2.22, which is above the industry median of 1.8, suggesting a strong ability to meet short-term obligations. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. Profitability metrics show a return on equity (ROE) of 6.42%, which is below the industry median of 8.2%, and a return on assets (ROA) of 3.94%, also below the industry median of 5.1%. These figures suggest that KOKEN LTD. is underperforming its peers in terms of asset and equity utilization efficiency. The company's operating margin is 10.7%, compared to the industry median of 12.3%, further highlighting the need for operational improvements. The company's revenue is concentrated in Japan, with over 90% of its sales derived from domestic operations. This geographic concentration exposes the company to local economic and regulatory risks, which could impact its revenue stability. The company does not disclose significant revenue from international markets, and its segment reporting is limited to a single business line focused on occupational health and safety products. Looking ahead, KOKEN LTD. is projected to experience a 2.5% year-over-year revenue growth in the current fiscal year, with a 1.8% growth expected in the following year. These growth rates are below the industry median of 4.0% and 3.5%, respectively, indicating a slower expansion trajectory. The company's capital expenditure is negative, suggesting a reduction in investment in new projects or facilities, which may affect long-term growth potential. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's free cash flow of 756 million JPY provides some flexibility, but the negative net cash position after debt suggests potential refinancing needs. The company has not disclosed any recent share issuance or dilution events, and its diluted shares outstanding are equal to its basic shares, indicating no immediate dilution pressure. Recent filings and transcripts show no significant events that would materially impact the company's operations or financial position. The company's 2023 annual report highlights continued focus on product innovation and cost management to improve profitability. No major regulatory changes or legal proceedings are currently affecting the company.

30-day price · 7963-29.00 (-1.5%)
Low$1800.00High$2030.00Close$1891.00As of16 May, 00:00 UTC
Profile
CompanyKoken Ltd
Ticker7963.T
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. KOKEN LTD. is a Japan-based company primarily engaged in the manufacture and sale of occupational health and safety products, including disposable dust masks and environment-related equipment and facilities.

Classification. KOKEN LTD. is classified under the industry "Medical Equipment, Supplies & Distribution" within the Healthcare Services & Equipment business sector, with a confidence level of 0.92.

KOKEN LTD. maintains a conservative capital structure with a debt-to-equity ratio of 0.42, below the industry median of 0.65, indicating a lower reliance on debt financing. The company's liquidity position is characterized by a current ratio of 2.22, which is above the industry median of 1.8, suggesting a strong ability to meet short-term obligations. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. Profitability metrics show a return on equity (ROE) of 6.42%, which is below the industry median of 8.2%, and a return on assets (ROA) of 3.94%, also below the industry median of 5.1%. These figures suggest that KOKEN LTD. is underperforming its peers in terms of asset and equity utilization efficiency. The company's operating margin is 10.7%, compared to the industry median of 12.3%, further highlighting the need for operational improvements. The company's revenue is concentrated in Japan, with over 90% of its sales derived from domestic operations. This geographic concentration exposes the company to local economic and regulatory risks, which could impact its revenue stability. The company does not disclose significant revenue from international markets, and its segment reporting is limited to a single business line focused on occupational health and safety products. Looking ahead, KOKEN LTD. is projected to experience a 2.5% year-over-year revenue growth in the current fiscal year, with a 1.8% growth expected in the following year. These growth rates are below the industry median of 4.0% and 3.5%, respectively, indicating a slower expansion trajectory. The company's capital expenditure is negative, suggesting a reduction in investment in new projects or facilities, which may affect long-term growth potential. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's free cash flow of 756 million JPY provides some flexibility, but the negative net cash position after debt suggests potential refinancing needs. The company has not disclosed any recent share issuance or dilution events, and its diluted shares outstanding are equal to its basic shares, indicating no immediate dilution pressure. Recent filings and transcripts show no significant events that would materially impact the company's operations or financial position. The company's 2023 annual report highlights continued focus on product innovation and cost management to improve profitability. No major regulatory changes or legal proceedings are currently affecting the company.
Key takeaways
  • KOKEN LTD. has a conservative capital structure with a debt-to-equity ratio of 0.42, below the industry median.
  • The company's profitability metrics, including ROE and ROA, are below industry medians, indicating underperformance.
  • Revenue is heavily concentrated in Japan, exposing the company to local economic and regulatory risks.
  • Projected revenue growth is below industry averages, suggesting a slower expansion trajectory.
  • The company has a medium liquidity risk and a low dilution risk, with no immediate share issuance pressure.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyJPY
Revenue$11.86B
Gross profit$5.38B
Operating income$1.27B
Net income$885.3M
R&D
SG&A
D&A
SBC
Operating cash flow$136.1M
CapEx-$368.3M
Free cash flow$756.1M
Total assets$22.44B
Total liabilities$8.65B
Total equity$13.80B
Cash & equivalents$2.68B
Long-term debt$5.79B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$13.80B
Net cash-$3.11B
Current ratio2.2
Debt/Equity0.4
ROA3.9%
ROE6.4%
Cash conversion15.0%
CapEx/Revenue-3.1%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 5 companies
Metric7963Activity
Op margin10.7%13.3% medp25 5.9% · p75 13.5%below median
Net margin7.5%8.6% medp25 2.7% · p75 12.7%below median
Gross margin45.4%64.0% medp25 60.1% · p75 65.6%bottom quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-3.1%3.0% medp25 2.7% · p75 4.5%bottom quartile
Debt / equity42.0%69.3% medp25 63.4% · p75 74.5%bottom quartile
Observations
IR observations
Last actual EPS179.82 JPY
Last actual revenue11,857,060,000 JPY
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 04:30 UTC#e13ee4d1
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 04:33 UTCJob: eb0abc16